TMX group

TORONTO, Nov. 7 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) today
announced its role as a major partner in the International Sepsis Forum (ISF)
Biomarker Conference recently held in Toronto, Canada. The main goal of the
conference was to draft consensus recommendations for the inclusion of certain
biomarkers into mainstream clinical practice in patients with sepsis.
Biomarkers have proven to be very useful in clinical situations such as heart
attack and congestive heart failure. This conference is the first to focus on
sepsis biomarkers and incorporating them into clinical practice.
Dr. Paul Walker, MD, CEO of Spectral stated, "It has been a great honor
to take a significant role at this meeting. The ISF recommendations will help
shape the future of sepsis diagnosis and treatment. The measurement of
endotoxin continues to be a leading candidate to be widely adopted into
clinical practice for patients with suspected sepsis. The importance of
endotoxin measurement continues to grow as more clinicians recognize the added
value of measuring endotoxin in critically ill patients and with the emergence
of major pharmaceutical trials directly targeting endotoxin in the
bloodstream." Spectral's Endotoxin Activity Assay (EAA(TM)) provides
physicians the ability to rapidly and accurately determine endotoxin levels in
a critically ill patient.
The International Sepsis Forum (ISF) seeks to improve the understanding
and clinical management of patients with severe sepsis through workshops,
lectures, debates, practice guidelines, and training programs for
professionals worldwide. The ISF is a partnership of leading global experts
and industry partners in the sepsis area. Severe sepsis is one of the most
significant challenges in critical care. Each year, more than 750,000 people
in the U.S. will develop severe sepsis, and more than 215,000 will die from
the condition. Treating patients with severe sepsis costs U.S. hospitals
nearly $17 billion a year.
"This ISF conference reaffirms the value of Spectral's EAA(TM) program.
Spectral's strategy of continuing clinical promotion with the most important
thought leaders and academic centers in critical care, together with ongoing
studies aimed at expanding the EAA(TM) into other critical disease areas such
as renal failure, burns, trauma, and transplantation, continues to progress
well" added Debra Foster, Clinical Director of Spectral's Sepsis Program.

Spectral is a developer of innovative technologies for comprehensive
disease management. Spectral provides accurate and timely information to
clinicians enabling the early initiation of appropriate and targeted therapy.
Current products are rapid format tests measuring markers of myocardial
infarction (Cardiac STATus test). New products include rapid diagnostics for
sepsis (the Endotoxin Activity Assay). Spectral manufactures the EAA(TM) and
Cardiac STATus. Spectral's common shares are listed on The Toronto Stock
Exchange: SDI.

This press release contains certain forward-looking statements and
information based on beliefs of the Company's senior management as well as
assumptions made by, and information currently available to it. Such
statements reflect the current views of the Company with respect to future
events and are subject to certain risks and uncertainties. Actual results,
events, and performance may differ materially. Readers are cautioned not to
place undue reliance on these forward-looking statements, which speak only as
of the date hereof.
%SEDAR: 00002006E